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ABSTRACT
Engineered nucleases, which incise the genome at
predetermined sites, have a number of laboratory
and clinical applications. There is, however, a need
for better methods for controlled intracellular
delivery of nucleases. Here, we demonstrate a
method for ligand-mediated delivery of zinc finger
nucleases (ZFN) proteins using transferrin
receptor-mediated endocytosis. Uptake is rapid
and efficient in established mammalian cell lines
and in primary cells, including mouse and human
hematopoietic stem-progenitor cell populations. In
contrast to cDNA expression, ZFN protein levels
decline rapidly following internalization, affording
better temporal control of nuclease activity. We
show that transferrin-mediated ZFN uptake leads
to site-specific in situ cleavage of the target locus.
Additionally, despite the much shorter duration
of ZFN activity, the efficiency of gene correction
approaches that seen with cDNA-mediated expres-
sion. The approach is flexible and general, with the
potential for extension to other targeting ligands
and nuclease architectures.
INTRODUCTION
Engineered nucleases, including zinc finger nucleases
(ZFNs), TAL effector nucleases and RNA-guided
endonucleases are useful for targeted genome modification
[reviewed in (1–4)]. They incise the genome at pre-
determined sites to create DNA double-strand breaks.
These breaks can be repaired by two general mechanisms.
Non-homologous end joining rejoins broken ends directly,
sometimes with deletions or insertions leading to loss of
gene function. Homologous recombination uses a donor
template to synthesize DNA across the break site. This
leads to genome modification when the donor template
differs from the original sequence, as when a wild-type
sequence is used to replace its mutant counterpart, result-
ing in gene correction. Examples of laboratory and clinical
applications for engineered nucleases include the creation
of knockout animal models (5–7), generation of HIV-
resistant hematopoietic stem cells (8) and correction
of the X-linked severe combined immunodeficiency
mutation in human cells (9).
One of the limiting factors in the use of ZFNs and other
engineered nucleases, particularly for clinical applications,
is the need to gain better control over the amount of
nuclease delivered and the duration of nuclease activity.
Vector-mediated cDNA expression, which is the standard
delivery method, suffers from the limitation that it
promotes prolonged and uncontrolled expression, poten-
tially leading to off-target cutting and significant toxicity.
Another limitation of cDNA expression, as evidenced by
recent work with homing endonucleases (another type of
rare-cutting nuclease), is variation in nuclease levels
between cells in the target population, which has substan-
tial effects on repair outcome (10). Transfection of
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nuclease-encoding mRNAs in place of cDNAs shortens
the duration of ZFN expression and has shown promise
in the generation of genetically modified animals (5–7),
although it has not yet been fully evaluated for human
somatic cells.
An entirely different approach is based on direct
delivery of nucleases as proteins. Recent work provides
proof of concept that ZFNs can be delivered in this
manner, by taking advantage of their intrinsic cell-
penetrating capability (11). The zinc finger domains of
ZFNs fall into the category of the so-called ‘supercharged’
proteins, i.e. proteins with a very high net positive charge
to mass ratio (12,13). As is the case with positively charged
cell-penetrating peptides, supercharged proteins enter
cells directly through multiple pathways, including
macropinocytosis and clathrin-dependent endocytosis
(14). Although successful for ZFNs, this method of
uptake has some limitations, as it requires relatively high
protein concentrations, is limited to highly charged pro-
teins and likely occurs by a nonspecific mechanism.
We hypothesized that addition of a targeting ligand to
ZFNs might help overcome these limitations. Ligand-
mediated targeting significantly enhances delivery of a
variety of drugs, proteins and nanoparticles [reviewed in
(15,16)]. For intracellular protein delivery, the ligand is
often attached via a scissile (‘self-immolative’) disulfide
linker, which allows separation of ligand-cargo complex
in the intracellular reducing environment (17,18). In the
present study, we used transferrin as the ligand for ZFN
delivery. We show that transferrin-ZFNs are taken up
rapidly at 50–100 nM concentrations, under conditions
where there was no detectable uptake of unmodified
ZFNs. ZFNs delivered by the ligand-targeting method
escape the endocytic compartment and enter the nucleus,
where they mediate target gene cleavage and gene correc-
tion with an efficiency approaching that seen with vector-
mediated cDNA expression. Ligand-mediated nuclease
delivery has the potential for broad application, as it can
be readily adapted for ligands other than transferrin and
for other engineered nuclease architectures.
MATERIALS AND METHODS
Cells and culture conditions
HEK-293/A658 (19) and U2OS 2-6-3 (20) cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
with GlutaMAX-1 (Invitrogen Life Technologies, Grand
Island, NY) supplemented with 10% fetal bovine serum,
and penicillin/streptomycin. Primary ROSA26GFP*/*
fibroblasts were obtained by standard methods using
mouse ears as the tissue source (21).
Human CD34+ hematopoietic stem-progenitor cells
(HSPCs) were purchased from StemCell Technologies
(Vancouver, BC, Canada) and expanded for 48 h in
serum-free IMDM (Invitrogen Life Technologies) supple-
mented with BIT 9500 (StemCell Technologies), 100 ng/ml
human SCF, 100 ng/ml human Flt3-L and 20 ng/ml human
thrombopoietin (StemCell Technologies). Mouse HSPCs
[lineage marker negative, sca-1 positive, c-kit positive
(LSK)] were obtained from mouse bone marrow and
expanded as described (22). After 9 days, cells were
stained with biotinylated lineage marker cocktail
antibodies (anti-TER119, anti-Gr1, anti-Mac1, anti-
B220, anti-CD8, anti-CD4), streptavidin-APC-Cy7, anti-
Sca-1-APC and anti-c-Kit-PE (all from BD Pharmingen,
San Diego, CA). LSK cells were isolated by flow
cytometry.
Preparation of ZFNs and transferrin-ZFN conjugates
GFP-ZFN1 and GFP-ZFN2 (23) were cloned into the
Not/BamHI sites of pHIS-parallel (24) and transformed
into Escherichia coli Rosetta 2 (EMD Millipore,
Gibbstown, NJ, USA). Expressed proteins contained the
following elements: hexahistidine tag, Tev protease site,
FLAG epitope tag, nuclear localization sequence, triple
tandem zinc finger domain and FokI dimerization and
catalytic domain. Escherichia coli cultures were grown in
an NBS 110 fermentor to OD600& 2, cooled to 18C and
incubation was continued to OD600& 4. Cultures were
adjusted to 0.2mM isopropyl thiogalactoside, 100 mM
ZnCl2 and incubation was continued 16–18 h to
OD600& 14. Cells from 3 l of culture were resuspended
in 200ml of lysis buffer [20mM Tris–HCl (pH 8.0),
300mM NaCl, 10mM b-mercaptoethanol, 0.1% Tween-
20, 100 mM ZnCl2], sonicated and centrifuged at 10 000g
for 25min at 4C. Cleared lysates were subjected to chro-
matography using a 5ml of immobilized HIS-Select nickel
affinity column (Sigma-Aldrich, St. Louis, MO, USA),
which was equilibrated in lysis buffer containing 25mM
imidazole and eluted in lysis buffer adjusted to pH 7 and
containing 150mM imidazole. Non-conjugated ZFNs
were further purified by Superdex S-75 chromatography
(GE Healthcare Life Sciences, Piscataway NJ) in phos-
phate buffered saline (PBS) supplemented with 0.25M
NaCl. ZFN-containing fractions were adjusted to 10%
glycerol, aliquoted and stored at 80C.
For conjugation, human holo-transferrin (10mg in 1ml
of PBS) (Akron Biotechnology, Boca Raton, FL) was
reacted with 1mM sulfosuccinimidyl 6-[30(2-
pyridyldithio)-propionamido] hexanoate (SPDP; Pierce
Biotechnology, Rockford, IL, USA) for 1 h at room tem-
perature. After desalting (PD10 column, GE Life Sciences,
Piscataway, NJ), 1.4mg of the activated transferrin was
incubated overnight at 4C with a 2-fold excess of nickel
affinity-purified ZFN. Conjugates were isolated by
Superdex S-75 chromatography and stored in the same
way as non-conjugated ZFNs.
In vitro ZFN cleavage assays
Linear substrate DNA was prepared by AlwNI digestion
of pPC264 plasmid DNA (21). Reactions contained
20mM Tris–HCl (pH 8.0), 150mM NaCl, 2.5mM
MgCl2, 10mM b-mercaptoethanol, 100 mM ZnCl2,
0.1mg/ml bovine serum albumin, 2.6 nM gel-purified
DNA and ZFNs or transferrin-ZFN conjugates, in a
volume of 20 ml. Reactions were incubated for 1 h at
30C and analyzed by agarose gel electrophoresis.
Quantification was performed by scanning SYBR Green
I-stained gels (Invitrogen, Carlsbad, CA) using a Typhoon
Trio imager (GE Healthcare Life Sciences).
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Measurement of uptake in immunofluorescence assays
Adherent cells were seeded at a density of 5 104 on cover
slips in 24-well plates. After 24 h, 1mg of ZFN1/2 expres-
sion plasmid (21) was delivered using Lipofectamine 2000
(Invitrogen Life Technologies). Alternatively, transferrin-
ZFNs were delivered by washing cells twice with serum-
free medium and incubating with 100 nM transferrin-ZFN
in 200 ml of serum-free medium for 1 h at 37C.
Suspension cells (HSPCs) were washed with IMDM con-
taining 1% bovine serum albumin, then incubated with
transferrin-ZFNs in IMDM supplemented with 100 mM
ZnCl2.
For immunofluorescence, cells were washed with PBS,
fixed with 4% paraformaldehyde in PBS for 20min at
room temperature, washed, permeabilized with 0.1%
Triton X-100 for 5min on ice and blocked with 2%
bovine serum albumin for 1 h at room temperature.
Cells were stained with 1:200 anti-FLAG monoclonal
antibody (#GTX80656; GeneTex Inc. Irvine, CA) at 4C
overnight and 1:500 Texas Red goat anti-mouse IgG2b
(sc-2981; Santa Cruz Biotechnologies, Santa Cruz, CA)
at room temperature for 1 h. After washing, cover slips
were mounted using UltraCruz Mounting Medium
DAPI (Santa Cruz Biotechnologies). Image stacks
(0.2 mm) were collected using a Deltavision microscope
(Applied Precision Inc., Issaquah, WA, USA) and
deconvolved. Signal was quantified from projections of
depth-coded Z-stacks.
Measurement of uptake in immunoblotting assays
Cells (1.75 105 per well in poly-L-lysine-coated plates)
were transfected or treated with 200 nM transferrin-ZFN
for 1 h at 37C, washed twice with DMEM and incubation
was continued in DMEM. At intervals, lysates were
prepared in RIPA buffer containing protease and phos-
phatase inhibitors (Santa Cruz Biotechnology). Equal
protein amounts (45 mg) of each sample were resolved
by SDS–PAGE using 4–20% precast gels and transferred
to Immun-Blot polyvinylidene difluoride membranes (Bio-
Rad Laboratories, Hercules CA). These were blocked with
5% bovine serum albumin in Tris-buffered saline with
0.1% Tween 20 and probed with anti-FLAG primary
antibody (#F1804; Sigma-Aldrich, St. Louis, MO) at
4C overnight and horseradish peroxidase-conjugated sec-
ondary antibody (#626820; Invitrogen) at room tempera-
ture for 1 h. Membranes were stripped and re-probed with
anti-a-actin (Santa Cruz Biotechnologies). Immune
complexes were visualized with the ECL system (Bio-
Rad Laboratories). Scanned images were quantified
using Image J (http://rsbweb.nih.gov/ij).
In situ cleavage assay
For experiments shown in Figure 5, U2OS 2-6-3 cells (20)
were transfected with 2 mg/well pSV2-lacI-ECFP (created
by swapping enhanced cyan fluorescent protein (ECFP)
into pSV2-lacI-EYFP). After 24 h, cells were incubated
with 120 nM each of transferrin-ZFN1 and transferrin-
ZFN2 at 37C for 2 h. Cells were fixed as described previ-
ously and stained with 1:200 rabbit anti-53BP1 (#4937,
Cell Signaling Technology, Danvers, MA, USA) at 4C
overnight and with 1:500 Alexa Fluor 594-goat anti-
rabbit IgG (#A11012, Invitrogen Life Technologies) for
1 h at room temperature. Two independent observers
scored cells blindly for co-localization of LacI-ECFP and
53BP1 foci. Experiments in Supplementary Figure S4 were
performed similarly except that cells were transfected with
cDNA vectors expressing ZFN1, ZFN2 or ZFN1/2 rather
than being treated with transferrin-ZFN. Additionally,
cells were transfected with mCherry-53BP1 (rather than
stained for endogenous 53BP1) and fixation and imaging
was as described (25).
Gene correction
HEK-293/A658 cells (1.75 105) were seeded on cover-
slips in a 24-well plate and transfected with 0.1 mg/well
ZFN1/2 expression plasmid, 0.9 mg of donor template
plasmid or both. After 24 h, some groups were
incubated with 100 nM each of transferrin-ZFN1 and
transferrin-ZFN2 for 2 h at 37C, washed twice and incu-
bation was continued in growth medium for 3 days
to allow green fluorescent protein (GFP) expression.
Live cells were observed by fluorescence microscopy, and
fixed cells were analyzed by flow cytometry.
Viability assay
Cells were incubated with 100 nM each of transferrin-
ZFN1 and transferrin-ZFN2 for 90min at 37C, washed
twice and culture was continued in growth medium for
the indicated times. Cell viability was determined with
the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT)] assay according to the vendor’s instruc-
tions (Biotium, Hayward, CA) and absorbance measured
on an enzyme-linked immunosorbent assay plate reader
with a test and reference wavelength of 570 and 630 nm,
respectively.
RESULTS
Principle of the method
A schematic representation of transferrin-ZFN conjuga-
tion is shown in Figure 1A. Human holo-transferrin was
activated by controlled reaction with SPDP, a crosslinker
for amine-to-sulfhydryl conjugation. Activated transferrin
was reacted with ZFNs to form a cleavable disulfide bond
with a single non-liganded cysteine residue present near
the N-terminus of the ZFN.
Figure 1B shows the pathway for transferrin receptor-
mediated uptake and delivery of ZFNs to the cell
nucleus. Transferrin-ZFNs bind the ubiquitous plasma
membrane transferrin receptor (step 1). They are
internalized to the endosomal compartment, where the
reducing environment promotes cleavage of the scissile
disulfide bond (step 2). ZFNs then exit the endosomal
compartment (step 3), enter the nucleus and bind to
and cleave their target sequence within a GFP transgene
(step 4).
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Production and characterization of transferrin-ZFNs
To prepare transferrin-ZFNs, recombinant ZFN proteins
were expressed in E. coli and purified by immobilized
nickel affinity chromatography (Supplementary Figure
S1). ZFNs were incubated with activated transferrin,
and conjugates were isolated by gel filtration chromatog-
raphy, where they eluted ahead of unreacted transferrin
and ZFN (Figure 2A). The column fractions were
analyzed by SDS–PAGE (Figure 2B). Under non-
reducing conditions, conjugates migrated near the top of
SDS–PAGE gels, whereas under reducing conditions, the
disulfide linker was cleaved to regenerate more rapidly
migrating free transferrin and ZFNs. Comparison of the
amount of ZFN that eluted in the transferrin-ZFN peak
versus the amount that eluted later (Figure 2B, lower
panel, fractions B4–B7 versus C2–C6) suggests that one-
quarter to one-third of the input ZFN was recovered as
conjugate.
We investigated the effect of conjugation on ZFN
activity and specificity. Efficient ZFN-mediated cleavage
requires heterodimerization of ZFN1 (which recognizes a
DNA sequence on one side of the cleavage site) and ZFN2
(which recognizes a DNA sequence on the other). In the
example shown, varying amounts of transferrin-ZFN2 or
non-conjugated ZFN2 were mixed with a constant
amount of ZFN1 and tested for the ability to cleave a
linear target DNA. About twice as much transferrin-
ZFN2 was required to give the same cleavage, indicating
a modest loss of activity and no loss of specificity
(Figure 2C and D). Similar results were obtained when
varying amounts of transferrin-ZFN1 or non-conjugated
ZFN1 were mixed with a constant amount of ZFN2 and
tested in the same way (Supplementary Figure S2).
Finally, incubation of substrate DNA with an equimolar
mixture of transferrin-ZFN1 and transferrin-ZFN2 also
gave complete and specific cleavage (Figure 2E). We
noted that there was also some site-specific cleavage by
transferrin-ZFN2 alone at this concentration, perhaps
reflecting homodimerization in solution, followed by tran-
sient interaction of transferrin-ZFN2 with its half site. We
have seen the same phenomenon with non-conjugated
ZFNs (LJ and WSD, unpublished).
Receptor-ligand-mediated delivery of transferrin-ZFNs
to cells
We evaluated functional characteristics of transferrin-
ZFNs in cells. For this purpose, we assembled a collec-
tion of different cell types, including HEK293/A658, a
human embryonic kidney cell line modified to create a
gene correction model (19); U2OS 2-6-3, a human osteo-
sarcoma line bearing a multicopy ZFN target array, (20)
and ROSA26GFP*/*, a primary fibroblast strain derived
from a mouse gene correction model (21). We also tested
human and mouse HSPCs (human CD34+cells and mouse
LSK cells), obtained as described in ‘Materials and
Methods’ section. In all cases, cells were exposed to trans-
ferrin-ZFN for 1 h, fixed and stained. For established cell
lines and strains, we performed conventional vector-
mediated cDNA expression as a positive control.
Figure 3 presents a gallery of immunofluorescence
images. Each panel represents a single optical section
obtained by deconvolution microscopy. Transferrin-ZFN
uptake was detected in all cells lines tested. Uptake
occurred in virtually 100% of cells in each population,
as seen in the micrographs (Figure 3), and confirmed in
some instances by flow cytometry (data not shown). ZFN
uptake was seen in both the nucleus and cytoplasm, in a
ratio that varied between cell types. Where tested, the
amount and distribution of intracellular ZFNs was
similar in transferrin-ZFN treated and cDNA-transfected
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Figure 1. Receptor mediated delivery concept. (A) Conjugation scheme. Human holo-transferrin was activated by incubation with SPDP, and
conjugates were isolated and incubated with purified ZFN as described in ‘Materials and Methods’ section. A scissile disulfide bond joins the
transferrin and the ZFN. (B) Cellular delivery. 1. The transferrin-nuclease complex binds to its cognate receptor, which induces uptake of the cargo
to the cell interior in the early recycling endosome. 2. Under the reducing conditions of the endosomal milieu, the ZFN protein is released from the
ligand-receptor complex by ‘self-immolation’ of the disulfide bond. 3. ZFN protein escapes the endosome. 4. ZFN protein translocates to the cell
nucleus where the two ZFN subunits bind to opposing DNA strands and cleave the target sequence. Pm, plasma membrane; End, endosome; Nuc,
nucleus.
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populations. Control experiments in the HEK-293T cells
showed that transferrin-ZFN uptake was competed by
free transferrin, that there was no detectable uptake of
non-conjugated control ZFNs when tested at the same
concentration. As expected, there was no signal in
mock-treated control cells. Together, results indicate that
delivery is efficient, that the method is applicable to a wide
range of cell types and that the uptake is mediated via the
transferrin receptor.
In HEK293/A658 cells, ZFN concentrations of
50–100 nM were sufficient for maximum uptake, with no
further increase at 200 nM (Figure 3B). Intranuclear ZFN
levels reached a peak after 1 h of incubation, with longer
incubations leading to a steady decline (Figure 3C).
Uptake in HSPCs (Figure 3F and G) is significant
because these are the relevant cell type for many potential
applications of engineered nuclease technology. HSPCs,
particularly in the mouse, are refractory to DNA transfec-
tion, suggesting that receptor-mediated delivery may have
a particular advantage over conventional methods.
The transferrin-ZFN delivery approach is based on the
idea that transferrin (the carrier) and ZFN (the cargo)
dissociate following cleavage of the disulfide linker in the
early endosome. We tested this idea directly in the mouse
HSPCs by comparing the fate of transferrin (detected
using an AlexaFluor 488 conjugate) with that of ZFNs
(detected via immunostaining). Alexafluor-transferrin
accumulated in the thin rim of cytoplasm surrounding
the nucleus, whereas ZFN cargo accumulated within the
nucleus, consistent with prediction (Figure 3G).
To investigate whether transferrin-ZFN treatment
resulted in significant toxicity, we performed MTT viabil-
ity assays comparing transferrin-ZFN treated, cDNA-
transfected and control HEK-293/A658 cells. There was
no significant difference between groups at times between
24 and 72 h post-treatment (Supplementary Figure S3).
Rapid intracellular turnover following uptake of
transferrin ZFNs
Part of the rationale for developing a protein-based
delivery system was to gain better control over the
timing and duration of nuclease exposure. To further
evaluate the kinetics of ZFN uptake and turnover, we
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incubated HEK-293/A658 cells with transferrin-ZFNs for
1 h, transferred to fresh medium and harvested at intervals
for analysis. Maximum ZFN levels were seen within 0.5 h,
at the earliest time point tested, and declined rapidly fol-
lowing withdrawal of transferrin-ZFN-containing
medium. Levels were nearly undetectable at 3.0 h (Figure
4A).
For comparison, we performed a parallel experiment in
which cells were transfected with ZFN1/2-expressing
plasmid (Figure 4B). The onset of expression was much
slower, reflecting the need for transcription, mRNA pro-
cessing and translation. Peak levels were not reached until
24 h post-transfection. The duration of nuclease exposure
was also much longer, persisting at relatively high levels
through 48 h post-transfection, but declining to an
undetectable level at 72 h. Together, these results indicate
that although bothmethods achieve comparable peak ZFN
levels, protein delivery affords much better temporal
control, increasing and declining for a far shorter period.
Transferrin-ZFNs cleave a predetermined genomic site
in situ in living cells
To evaluate the ability of the transferrin-ZFN delivery
system to induce cleavage at a genomic recognition site,
we tested their activity in the U2OS 2-6-3 cell line, which
harbors a 200 copy tandem double-strand break
reporter array integrated at a single genomic site (20,25).
A schematic showing the elements that make up the
tandem repeat is shown in Figure 5A. Each tandem
D
N
A 
(D
AP
I)
ZF
N
 (a
nti
-F
LA
G)
mockZFN cDNA tf-ZFN1 protein
ZFN1 protein
(no tf conjugation)
m
e
rg
e
A HEK-293/A658 cells
E
tf-ZFN1 protein
free transferrin
D
N
 
(D
AP
I)
A
ZF
N
 (a
nti
-F
LA
G)
F
0
50
100
150
200
250
300
0
40
20
80
60
100
120
140
160
180
B
[tf-ZFN1] (nM)
re
la
tiv
e 
flu
or
es
ce
nc
e
C
time (h)
re
la
tiv
e 
flu
or
es
ce
nc
e
GD
0
0 0.5 1.0 1.5 2.0 3.0 4.0
6.3 12.5 25 50 100 200cDNA
cDNA
tf-ZFN1 protein
murine HSPC (LSK)
AF-transferrin
human CD34+
tf-ZFN1 protein
U2OS 2-6-3 cells
tf-ZFN1 proteinZFN cDNA
ROSA26GFP*/* fibroblasts
tf-ZFN1 proteinZFN cDNA
Figure 3. Cellular delivery of transferrin-conjugated ZFN. (A) ZFN protein levels in HEK293/A658 cells visualized by indirect immunofluorescence
using ant-FLAG primary antibody. Cells were transfected with ZFN1/2 cDNA. Alternatively, they were incubated with 100 nM transferrin-ZFN1, or
100 nM non-conjugated ZFN1, as indicated, for 1 h at 37C. Competition experiments were performed with a 10-fold molar excess of free holo-
transferrin. Z-stacks were collected with a Deltavision microscope and deconvolved. Each panel corresponds to a single Z-section. (B) Quantification
of nuclear uptake of tf-ZFN1 protein based on anti-FLAG fluorescence intensity. HEK293/A658 cells were incubated for 60min with various
concentration of tf-ZFN1 as indicated, then fixed and stained. Measurements were based on one representative Z-section from each of 25 cells total
(from five different fields) for each experimental group. Graph shows mean and standard deviation. (C) Quantification of nuclear uptake of tf-ZFN1
as in panel (B), except that tf-ZFN1 concentration was fixed at 100 nM, and continuous incubation was performed for the indicated times. (D) ZFN
protein levels in U2OS 2-6-3 human osteosarcoma cells. Cells were transfected with ZFN1/2 cDNA expression plasmid or incubated with tf-ZFN1
(100 nM, 60min) as indicated. (E) Same as panel (D) but with murine adult fibroblasts. (F) Same as panel (D) but with primary human HSPCs
(CD34+). (G) Same as panel (D) but with primary mouse HSPCs (LSK). Panels compare ZFN distribution with labeled free transferrin, note
difference in localization. Scale bars, 10 mm for panels (A–E), 5 mm for panels (F) and (G).
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element has a CFP gene, which contains the ZFN target
site and multiple copies of the lac operator. In addition,
there are various transcriptional control elements, but in
the experiments here, the inducer is not present, and the
array is transcriptionally silent (20). The principle of the
assay is to transfect with a plasmid encoding a LacI-ECFP
fusion protein, which homes to the transgene locus, expose
to ZFNs, fix and immunostain for 53BP1, a marker of
DNA double-strand breaks that can be measured. On-
target ZFN cleavage produces coincident 53BP1 and
LacI-ECFP foci, whereas spontaneous endogenous
double-strand breaks, or off-target ZFN cleavage,
produce non-coincident foci.
We validated the in situ cleavage assay by co-transfection
of LacI-EYFP, mCherry-53BP1 and ZFN1/2-encoding
cDNAs. Cells that received the ZFN cDNA pair, but not
control cells, showed coincident LacI-EYFP and 53BP1
foci (Supplementary Figure S4). The results demonstrate
the ability of the assay to distinguish on-target cleavage,
even in the presence of nonspecific background.
We then applied the assay to transferrin-ZFN-treated
cells. The results showed that coincident foci were present
in 19% of the transferrin-ZFN-treated cells (Figure 5B
and C) but were not present in any of the control cells,
indicating that transferrin-mediated ZFN delivery leads to
on-target cleavage in a substantial fraction of cells.
Transferrin-ZFN treatment apparently led to some
increase in the number of background foci (i.e. foci that
are not coincident with LacI-ECFP), as seen in represen-
tative images in Figure 5. However, the number of back-
ground foci in the absence of treatment was too high, and
their morphology was too diverse, to reliably quantify a
treatment effect.
Transferrin-ZFNs stimulate gene correction
Gene correction, using ZFN-induced DSBs to stimulate
homologous recombination with a wild-type donor
template to correct a gene defect, is a major application
of ZFN technology. We thus sought to investigate the
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Figure 4. ZFN protein levels in HEK293/A658 cells as measured by
immunoblotting. (A) Cells were incubated with 200 nM tf-ZFN1 for
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were incubated for a further 0–3 h as indicated, after which proteins
were extracted, resolved by SDS–PAGE and ZFN1 was detected by
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cates cells not treated with tf-ZFN1. (B) Same as panel (A), except
that cells were transfected with ZFN1/2 cDNA, incubated and
analyzed at indicated times. Note difference in time scale in panels
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ability of the transferrin-ZFN delivery approach to
promote gene correction using reporter cell systems.
Figure 6A shows a diagram of the reporter cassette in
HEK-293/A658 cells, in which it is integrated at a
random genomic site. ZFN cleavage is followed by hom-
ologous recombination repair using a donor template,
which results in conversion of an inactive to an active
GFP gene.
Cells were co-transfected with donor template and
treated, after 24 h, with the transferrin-ZFN protein
pair. Alternatively, as a positive control, cells were trans-
fected with a 1:9 mixture of ZFN1/2 cDNA expression
vector and donor template. After a 3-day expression
period, GFP-positive corrected cells were clearly seen by
fluorescence microscopy in treated populations, but not in
control populations (Figure 6B). Flow cytometry was used
to quantify the gene correction rate. Figure 6C shows rep-
resentative flow cytometry plots, and Figure 6D shows
combined results from replicate experiments. Treatment
with transferrin-ZFNs increases the frequency of gene
correction by about an order of magnitude over the back-
ground level. The frequency approaches that seen with
positive control populations that were transfected with
ZFN1/2 cDNAs.
DISCUSSION
We have developed a method for targeted delivery of en-
gineered nucleases based on receptor-mediated endocyto-
sis. We demonstrate the ability to conjugate a transferrin
ligand to a ZFN, with retention of enzymatic activity and
specificity. Ligand-conjugated, but not control, ZFNs are
taken up rapidly into a variety of cells, including primary
human and murine HSPCs. Once internalized, ZFNs
cleave their target sequence and promote gene correction
in the presence of donor template.
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A primary rationale for the present work was to develop
an alternative option for delivery of engineered nuclease
proteins into cells. One advantage of direct delivery of pro-
tein is improved temporal control. High levels of nuclease
were present for only 1–2 h, which compares favorably to
conventional methods based on vector-mediated cDNA
expression, where nuclease remained present at high
levels for about a day (i.e. from 24 to 48 h post-transfec-
tion). Prolonged expression may not be necessary for
cleavage of the intended target site, as gene correction
rates were only modestly lower with ligand-mediated
protein delivery compared with cDNA transfection. In
principle, shorter ZFN exposure should reduce the oppor-
tunity for cleavage and mutation at additional sites in the
genome, although a direct test of this will require whole
genome sequencing approaches that are beyond the scope
of the present study.
We note that direct protein delivery may afford other
advantages. For example, better temporal control over
expression may permit manipulations of the target cell
population that would not otherwise be feasible, such as
delivery to synchronized cell populations. Additionally, as
engineered nuclease technologies advance to clinical appli-
cation, the ability to dispense with expression vectors con-
taining strong exogenous transcriptional promoters could
provide a safety and regulatory advantage.
Like other ‘supercharged’ proteins, ZFNs have some
ability to enter cells via a non-specific process, without a
targeting ligand. However, the results here demonstrate
that transferrin conjugation significantly augments this
intrinsic cell penetrating capability; indeed, we were
unable to measure any uptake of non-conjugated ZFNs
under our experimental conditions, which used concentra-
tions that were about an order of magnitude lower than in
the earlier study (11). In our experience, ZFNs have a
tendency to aggregate and precipitate, both during expres-
sion in E. coli and when handled as purified protein at high
concentration. Thus, the inherently lower protein concen-
trations required for targeted delivery, which makes use of
high affinity ligand-receptor interaction, make the method
more scalable and practical for widespread adoption.
Ligand conjugation is a well-studied approach for
enhancing the delivery of conventional drugs and
nanoparticles (15,16) and faces no evident barriers to
clinical translation. Initial clinical applications for
ligand-conjugated ZFNs might involve ex vivo treatment
of isolated cells, such as HSPCs, followed by re-engraft-
ment to the patient. In such applications, in vivo stability
or clearance rates (which have not yet been investigated
for transferrin-ZFNs) would not be limiting.
It will be of interest to investigate the ability to apply
the method described here to other ligands and nuclease
architectures. ZFNs are the most well-established class of
engineered nucleases and, to our knowledge, are the only
ones to have entered clinical trials. TAL effector nucleases
and RNA guided endonucleases (e.g. CRISPR-Cas)
appear promising in laboratory studies, and, in principle,
a ligand-targeted delivery method should have many of
the same advantages as demonstrated here for ZFNs.
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